Status:
COMPLETED
Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects
Lead Sponsor:
Pfizer
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
PF 04603629 is a long acting exendin proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and glucose lowerin...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
- Hb A1c lower or equal to 11%
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Evidence of diabetic complications with significant end-organ damage
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00638313
Start Date
August 1 2007
End Date
February 1 2008
Last Update
July 31 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85013
2
Pfizer Investigational Site
San Antonio, Texas, United States, 78229